Outcomes and PFS at 24 Months for Patients With DLBCL Outcomes and PFS at 24 Months for Patients With DLBCL

The potential for positive survival outcomes is excellent in patients with DLBCL who have not progressed 24 months after receiving rituximab-containing immunochemotherapy.Annals of Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news